Back to top
more

BioRad Laboratories (BIO)

(Real Time Quote from BATS)

$265.66 USD

265.66
637

+1.34 (0.51%)

Updated Aug 7, 2025 09:58 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Hercules, CA, Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels in over 35 countries outside the United States through subsidiaries which focus on sales, customer service and product distribution.

Zacks Equity Research

Varian Medical (VAR) Q2 Earnings: Is a Surprise in Store?

by Zacks Equity Research

Strong revenue opportunity from various Oncology and Imaging Component products is likely to drive Varian Medical (VAR) in Q2.

    Zacks Equity Research

    Can Hospital-Products Unit Aid Baxter (BAX) in Q1 Earnings?

    by Zacks Equity Research

    Positive tidings on regulatory front, expanding Hospital-Products portfolio, strategic collaborations and strong presence in the international markets are key positives for Baxter's (BAX) Q1 results.

      Zacks Equity Research

      Can Neurotechnology & Spine Drive Stryker (SYK) Q1 Earnings?

      by Zacks Equity Research

      Stryker's (SYK) Neurotech business goes strong, VEXIM buyout likely to boost segment.

        Zacks Equity Research

        Will Core Segmental Growth Aid Stryker (SYK) in Q1 Earnings?

        by Zacks Equity Research

        Stryker's (SYK) acquisition-driven strategy is likely to boost Q1 results through the expansion of product offerings.

          Zacks Equity Research

          Can Instruments Drive Intuitive Surgical (ISRG) Q1 Earnings?

          by Zacks Equity Research

          Intuitive Surgical's (ISRG) developments on the da Vinci platform are a positive, while intense competition raises concern.

            Zacks Equity Research

            Can Solid Medical Devices Drive Abbott's (ABT) Q1 Earnings?

            by Zacks Equity Research

            Abbott (ABT) poised to gain on continued growth in Medical devices business in Q1.

              Zacks Equity Research

              Here's Why You Should Steer Clear of AmerisourceBergen Now

              by Zacks Equity Research

              AmerisourceBergen (ABC) continues to witness headwinds due to slowdown in hepatitis C revenues and conversion of branded drugs to the lower price generics.

                Zacks Equity Research

                Express Scripts (ESRX) to Launch Pilot Program, Shares Up

                by Zacks Equity Research

                Express Scripts (ESRX) aims to add value to patients' diagnosis in return for higher costs.

                  Zacks Equity Research

                  Pacific Biosciences Gains as HudsonAlpha Picks Sequel System

                  by Zacks Equity Research

                  Pacific Biosciences (PACB) sees increasing use of Sequel Sequencing System in pediatric and plant biologic case studies.

                    Zacks Equity Research

                    Can Solid EPD Business Drive Abbott's (ABT) Q1 Earnings?

                    by Zacks Equity Research

                    Abbott (ABT) poised to ride high on strength in EPD business in Q1.

                      Zacks Equity Research

                      Haemonetics Rides High on Plasma, Blood Center Remains Weak

                      by Zacks Equity Research

                      We are optimistic about Haemonetics' (HAE) improved Plasma franchise as strong end-market demand for plasma-derived biopharmaceuticals consistently drives growth for the company.

                        Zacks Equity Research

                        Masimo Gets CE Mark for NomoLine, Expands in Capnography

                        by Zacks Equity Research

                        Masimo (MASI) upgrades respiratory monitoring through the newly-approved Rad-97 Pulse Co-Oximeter with integrated capnography sampling lines.

                          Zacks Equity Research

                          Here's Why You Should Hold on to Ecolab (ECL) Stock for Now

                          by Zacks Equity Research

                          Ecolab (ECL) gains on core segmental business, while intense competition raises concern.

                            Zacks Equity Research

                            Texas Hospital Administers Cerner's (CERN) Millenium System

                            by Zacks Equity Research

                            Cerner's (CERN) EHR will provide comprehensive care to RHCD and improve patient engagement through a new online portal.

                              Zacks Equity Research

                              Here's Why You Should Invest in Fresenius Medical Right Now

                              by Zacks Equity Research

                              Fresenius Medical (FMS) receives a boost from solid guidance, higher geographical revenues and strategic acquisitions.

                                Zacks Equity Research

                                GNC Holdings Partners Rapid Nutrition, Forays in Australia

                                by Zacks Equity Research

                                GNC Holdings' (GNC) tie-up with Rapid Nutrition is likely to fuel the company's entry and expansion into the Australian healthcare market.

                                  Zacks Equity Research

                                  Supply Delay Hits Zimmer Biomet, Operational Plan Buoys Hope

                                  by Zacks Equity Research

                                  Zimmer Biomet's (ZBH) dull Knee sales continue to bother due to slower pace of supply recovery and sales recapture of certain key brands.

                                    Zacks Equity Research

                                    Henry Schein Ties Up With Internet Brands to Boost Dental Arm

                                    by Zacks Equity Research

                                    Henry Schein (HSIC) banks on part of its strategic plan, digital dentistry. In this regard, its latest joint venture with Internet Brands buoys optimism.

                                      Zacks Equity Research

                                      Stryker Loses 7.6% in a Month: What's Weighing It Down?

                                      by Zacks Equity Research

                                      Stryker's (SYK) declining margins and demand for healthcare products raise concern.

                                        Zacks Equity Research

                                        Hill-Rom Banks on Product Innovation, Strategic Buyouts

                                        by Zacks Equity Research

                                        Hill-Rom (HRC) sets sights on product innovation, the latest launch being Connex Cardio ECG. The company also revises its 2020 financial aims and outlook, backed by new tax reform-related benefits.

                                          Zacks Equity Research

                                          Cerner's EHR to Aid Kern Medical's Population Management

                                          by Zacks Equity Research

                                          Cerner's (CERN) coveted Millennium and HelatheIntent EHR platforms to overhaul Kern Medical's array of services.

                                            Zacks Equity Research

                                            Align Unveils Vivera Retainers for Deep Bite Correction

                                            by Zacks Equity Research

                                            Align (ALGN) hopes to taste greater clinical success in the orthodontic space with Vivera Retainers' integration into Precision Bite Ramps, which are part of the company's Invisalign G5.

                                              Zacks Equity Research

                                              Align Technology Broadens Invisalign Suite, Extends Reach

                                              by Zacks Equity Research

                                              Align Technology (ALGN) leaves no stone unturned to boost the Invisalign product portfolio and strengthen its hold in the high-potential invisible orthodontics market.

                                                Zacks Equity Research

                                                ABIOMED's (ABMD) Impella 5.5 Receives CE Mark in Europe

                                                by Zacks Equity Research

                                                ABIOMED's (ABMD) Impella line consistently boosts earnings in and outside the United States. Its Impella 5.5 successfully treats first patient at University Heart Center, Hamburg.

                                                  Zacks Equity Research

                                                  Myriad Genetics' BRACAnalysis Test Platform Gets PMA in Japan

                                                  by Zacks Equity Research

                                                  Myriad Genetics (MYGN) leaves no stone unturned to boost uptake of BRACAnalysis test and strengthen the Molecular Diagnostics portfolio.